Commentary

A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer’s Disease

Tobias Hartmann¹, Nick van Wijk², Richard J. Wurtman³, Marcel G.M. Olde Rikkert⁴, John W.C. Sijben², Hilkka Soininen⁵, Bruno Vellas⁶ and Philip Scheltens⁷,∗

¹Department of Neurodegeneration and Neurobiology, Deutsches Institut für Demenzprävention, Saarland University, Homburg, Germany
²Nutricia Research, Utrecht, The Netherlands
³Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
⁴Radboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Hospital, Nijmegen, The Netherlands
⁵Department of Neurology, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland
⁶Department of Internal and Geriatrics Medicine, Hôpitaux de Toulouse, Toulouse, France
⁷Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands

Accepted 27 May 2014

Abstract. Recently, a biomarker panel of 10 plasma lipids, including 8 phosphatidylcholine species, was identified that could predict phenocconversion from cognitive normal aged adults to amnestic mild cognitive impairment or Alzheimer’s disease (AD) within 2–3 years with >90% accuracy. The reduced levels of these plasma phospholipids could reflect altered phospholipid metabolism in the brain and periphery. We show that a 24-week nutritional intervention in drug-naïve patients with very mild to mild AD significantly increased 5 of the 7 measured biomarker phosphatidylcholine species. By providing nutrients which normally rate-limit phospholipid synthesis, this nutritional intervention could be useful in asymptomatic subjects with a plasma lipid biomarker profile prognostic of AD.

Keywords: Alzheimer’s disease, membranes, nutritional intervention, phosphatidylcholine, plasma phospholipids, prognostic biomarkers, synaptic dysfunction

INTRODUCTION

Mapstone et al. [1] recently identified and validated a set of 10 plasma lipids that could predict phenocconversion to either amnestic mild cognitive impairment (aMCI) or Alzheimer’s disease (AD). This 10 biomarker panel encompassed 8 phosphatidylcholine (PC) and 2 other molecules. Levels of these compounds were reduced in the plasma of the converter subjects (before conversion) compared to the non-convertors (normal control group). These metabolites remained low after conversion to aMCI/AD and were similar to the levels in the group with aMCI/AD at inclusion.

ISSN 1387-2877/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
As the authors indicated, the identified lipids have essential roles in the integrity and functionality of neuronal membranes, including synaptic membranes. The synapse loss and dysfunction characteristic of AD have been linked to the degeneration of neuronal membranes and increased breakdown of membrane phospholipids [2-4]. Mapstone et al. postulated that the observed changes in plasma phospholipid levels reflect the breakdown of neuronal membranes among individuals who convert within 3 years to aMCI/AD, and mark the preclinical transition to subtle cognitive changes [1]. Several other recent studies have demonstrated reduced plasma levels of several PC species in AD and MCI subjects [5-7], including some of the PCs identified by Mapstone et al., indicating altered phospholipid metabolism in AD. Whether the changes in plasma PCs concentration directly originate from disturbed PC metabolism in the brain, or are caused by disturbed PC metabolism in peripheral organs (e.g., liver) remains to be elucidated.

**OUR FINDINGS**

We previously tested, in drug-naïve patients with very mild to mild AD [8], the nutritional intervention Souvenaid® (125 mL, taken once daily) containing the specific nutrient combination Fortasyn® Connect in a 24-week, randomized, controlled, double-blind, parallel-group, multi-country trial. This nutrient combination was designed to enhance the formation and function of synaptic membranes and comprises uridine monophosphate (UMP, 625 mg), the long-chain omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA, 1200 mg) and eicosapentaenoic acid (EPA, 300 mg), choline (400 mg), phospholipids (106 mg), folate acid (400 µg), vitamin B12 (3 µg), vitamin B6 (1 mg), vitamin C (80 mg), vitamin E (40 mg), and selenium (60 µg) [8]. In the present study, some baseline and 24-week plasma samples, chosen at random, of subjects taking either the investigational product (n = 47) or a control product (n = 49) were analyzed using an analysis of covariance (ANCOVA) model. Five of the 7 measured PCs reported by Mapstone et al. [1], were significantly increased following the 24-week treatment with the nutrient combination (see Table 1). These results indicate that a biomarker profile reflecting disturbed phospholipid metabolism and perhaps indicative of early neurodegeneration can be modified in AD by providing nutrients which rate-limit phospholipid biosynthesis. These nutrients are substrates in the Kennedy pathway which synthesizes the phospholipids present in synaptic membranes [9, 10]. Enhancing the availability of these nutrients could thus increase synapse number and memory function in AD [11]. Previous observations from the same study indicate that the current changes in plasma PCs levels are accompanied by improved memory performance [8, 12] and preserved functional connectivity and brain network organization, as assessed by EEG analyses [13] in patients with mild AD, supporting the hypothesis that this nutritional intervention ameliorates synaptic dysfunction. Thus, these observations indicate that the changes in peripheral phospholipids may be indicative of the changes induced in the brain, i.e., increased synaptic membrane synthesis. It is reasonable to expect that the current nutritional intervention induces similar changes in the peripheral phospholipid levels in preclinical AD subjects, while the implications for disease risk modification are uncertain and need further investigation. In conclusion,
our findings suggest that a nutritional intervention that raises levels of nutrients normally rate-limiting in phospholipid synthesis may also be useful in asymptomatic subjects with plasma lipid biomarker profiles predictive for phenoconversion to aMCI/AD.

DISCLOSURE STATEMENT


REFERENCES


